Information de reference pour ce titreAccession Number: | 00002605-200807020-00010.
|
Author: | Caselli, D 1,5; Ziino, O 2; Bartoli, A 3; Santangelo, G 4; Vanadia, F 4; Arico, M 5
|
Institution: | (1)Cure Domiciliari e Terapia cellulare, AOU Meyer, Firenze, Italy; (2)Oncoematologia Pediatrica, Ospedale dei Bambini 'G. Di Cristina', ARNAS Civico, Palermo, Italy; (3)Unit of Pharmacokinetics, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy; (4)Neuropsichiatria infantile, Ospedale dei Bambini 'G. Di Cristina', ARNAS Civico, Palermo, Italy and (5)Dipartimento Onco-Ematologia Pediatrica, AOU Meyer, Firenze, Italy; E-mail: [email protected]
|
Title: | Continuous intravenous infusion of lorazepam as seizure prophylaxis in children treated with high-dose busulfan.[Letter]
|
Source: | Bone Marrow Transplantation. 42(2):135-136, July 2008.
|
References: | 1 Vassal G, Deroussent A, Hartmann O, Challine D, Benhamou E, Valteau-Couanet D et al. Dose-dependent neurotoxicity of high-dose busulfan in children: a clinical and pharmacological study. Cancer Res 1990; 50: 6203-6207.
2 Hassan M, Oberg G, Bjorkholm M, Wallin I, Lindgren M. Influence of prophylactic anticonvulsant therapy on high-dose busulphan kinetics. Cancer Chemother Pharmacol 1993; 33: 181-186.
3 Chan KW, Mullen CA, Worth LL, Choroszy M, Koontz S, Tran H et al. Lorazepam for seizure prophylaxis during high-dose busulfan administration. Bone Marrow Transplant 2002; 29: 963-965.
4 Treiman DM, Meyers PD, Walton NY, Collins JF, Colling C, Rowan AJ et al. A comparison of four treatments for generalized convulsive status epilepticus. Veterans affairs status epilepticus cooperative study group. N Engl J Med 1998; 339: 792-798.
5 Greenblatt DJ, von Moltke LL, Ehrenberg BL, Harmatz JS, Corbett KE, Wallace DW et al. Kinetics and dynamics of lorazepam during and after continuous intravenous infusion. Crit Care Med 2000; 28: 2750-2757.
6 Dominguez KD, Crowley MR, Coleman DM, Katz RW, Wilkins DG, Kelly HW. Withdrawal from lorazepam in critically ill children. Ann Pharmacother 2006; 40: 1035-1039.
7 Henner WD, Furlong EA, Flaherty MD, Shea TC, Peters WP. Measurement of busulfan in plasma by high-performance liquid chromatography. J Chromatogr 1987; 416: 426-432.
8 Tran HT, Madden T, Petropoulos D, Worth LL, Felix EA, Sprigg-Saenz HA et al. Individualizing high-dose oral busulfan: prospective dose adjustment in a pediatric population undergoing allogeneic stem cell transplantation for advanced hematologic malignancies. Bone Marrow Transplant 2000; 26: 463-470.
9 Zwaveling J, Bredius RG, Cremers SC, Ball LM, Lankester AC, Teepe-Twiss IM et al. Intravenous busulfan in children prior to stem cell transplantation: study of pharmacokinetics in association with early clinical outcome and toxicity. Bone Marrow Transplant 2005; 35: 17-23.
|
Language: | English.
|
Document Type: | Letter to the Editor.
|
Journal Subset: | Clinical Medicine.
|
ISSN: | 0268-3369
|
NLM Journal Code: | bon, 8702459
|
DOI Number: | https://dx.doi.org/10.1038/bmt.2...- ouverture dans une nouvelle fenêtre
|
Annotation(s) | |
|
|